tbuckley/cabot-search huggingface dataset:
Development of the autoinflammatory disease damage index (ADDI)
Authors: Nienke M ter Haar, Kim V Annink, Sulaiman M Al-Mayouf, Gayane Amaryan, Jordi Anton, Karyl S Barron, Susanne M Benseler, Paul A Brogan, Luca Cantarini, Marco Cattalini, Alexis-Virgil Cochino, Fabrizio De Benedetti, Fatma Dedeoglu, Adriana A De Jesus, Ornella Della Casa Alberighi, Erkan Demirkaya, Pavla Dolezalova, Karen L Durrant, Giovanna Fabio, Romina Gallizzi, Raphaela Goldbach-Mansky, Eric Hachulla, Veronique Hentgen, Troels Herlin, Michaël Hofer, Hal M Hoffman, Antonella Insalaco, Annette F Jansson, Tilmann Kallinich, Isabelle Koné-Paut, Anna Kozlova, Jasmin B Kuemmerle-Deschner, Helen J Lachmann, Ronald M Laxer, Alberto Martini, Susan Nielsen, Irina Nikishina, Amanda K Ombrello, Seza Ozen, Efimia Papadopoulou-Alataki, Pierre Quartier, Donato Rigante, Ricardo Russo, Anna Simon, Maria Trachana, Yosef Uziel, Angelo Ravelli, Marco Gattorno, Joost Frenkel
Journal: Annals of the Rheumatic Diseases (2016)

Objectives Autoinflammatory diseases cause systemic inflammation that can result in damage to multiple organs. A validated instrument is essential to quantify damage in individual patients and to compare disease outcomes in clinical studies. Currently, there is no such tool. Our objective was to develop a common autoinflammatory disease damage index (ADDI) for familial Mediterranean fever, cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic fever syndrome and mevalonate kinase deficiency. Methods We developed the ADDI by consensus building. The top 40 enrollers of patients in the Eurofever Registry and 9 experts from the Americas participated in multiple rounds of online surveys to select items and definitions. Further, 22 (parents of) patients rated damage items and suggested new items. A consensus meeting was held to refine the items and definitions, which were then formally weighted in a scoring system derived using decision-making software, known as 1000minds. Results More than 80% of the experts and patients completed the online surveys. The preliminary ADDI contains 18 items, categorised in the following eight organ systems: reproductive, renal/amyloidosis, developmental, serosal, neurological, ears, ocular and musculoskeletal damage. The categories renal/amyloidosis and neurological damage were assigned the highest number of points, serosal damage the lowest number of points. The involvement of (parents of) patients resulted in the inclusion of, for example, chronic musculoskeletal pain. Conclusions An instrument to measure damage caused by autoinflammatory diseases is developed based on consensus building. Patients fulfilled a significant role in this process.
Erythrocytosis in Chronic Mountain Sickness (CMS) in Andeans
Authors: Xunde Wang, David Callacondo, Jose Rojas, Jose Quesada-Olarte, Alan T. Remaley, Irina Maric, John F. Tisdale, Fabiola Leon-Velarde, Francisco Villafuerte, Matthew Hsieh
Journal: Blood (2014)
BIOMECHANICAL ANALYSIS WITH OPTIMAL COMBINATION BY USING FOOT AND DISTANCE WHEN THE FUTSAL PLAYER PASSING THE BALL AGAINST THE ACCURACY OF THE TARGET
Authors: S Fikri, F Pradhila, D Dirganta
Journal: British Journal of Sports Medicine (2016)

Futsal is one kind of soccer game. Recently, futsal become more popular around the world and also in Indonesia. In the futsal game, passing the ball is an important activity. However, many inaccuracies occurs when the futsal player pass the ball towards the target. Therefore, understanding the biomechanics analysis and the factors that affects the accuracy of the pass is important. The purpose of this study is to obtain the biomechanics analysis, understanding the factors that affect the accuracy of the target when futsal player pass the ball based on using the foot and the distance, and to obtain optimal combination between those factors. We performed an experiment in which 10 futsal playing men from Industrial Engineering, Universitas Indonesia to participate. Their average mass was 63±13 kg and the average height was 172±6 cm. The experiment was designed by using two-way factorial design. Each respondent was instructed to pass the ball to a target on four different conditions based on using the foot (inside foot and instep foot) and the distance (2 m and 3 m from the target). Platform 1 in AMTI Biomechanics Force Platforms BP400600H was used to collect the kinematics data from Ground Reaction Force (GRF) and Required Coefficient of Friction (RCOF). The results showed that the distance factor influences the accuracy of the pass with p-value=0.001 and the interaction between those factors by using the foot and the distance also has an effect on the GRF with p-value=0.005. The optimal combination from those factors when futsal player pass the ball by using the inside foot and the distance was 2 m with percentage of accuracy is 91±7 %. In this experiment the respondents were limited to using just one brand of futsal shoes with two different sizes. This results the compressive force and coefficient of friction forces obtained tend to be the same for every conditions. For the development of next researches, it is recommended to use more brands of shoes so that the factors mentioned before can be compared and so the optimum shoes condition on the physical performance of the player can be determined.
Validation of the Cibmtr Score in Predicting the Outcome of Hematopoietic Stem-Cell Transplantation in AML Patients Not in Complete Remission At the Time of Conditioning: A Retrospective Analysis On Behalf of the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO)
Authors: Elisabetta Todisco, Fabio Ciceri, Elena Oldani, Maria Teresa Van Lint, Irene Donnini, Francesca Patriarca, Emilio Paolo Alessandrino, Francesca Bonifazi, William Arcese, Anna Paola Iori, Paola Marenco, Elisabetta Terruzzi, Sergio Cortelazzo, Stella Santarone, Anna Proia, Paolo Corradini, Elena Tagliaferri, Sadia Falcioni, Giuseppe Irrera, Laura Dallanegra, Luca Castagna, Agnese Camboni, Alberto Bosi, Andrea Bacigalupo, Alessandro Rambaldi
Journal: Blood (2012)
Liposomal KRN7000 (RGI-2001) Synergizes with Low-Dose Rapamycin in Preventing GvHD by promoting expansion of naturally-Occurring CD4+FOXP3+ Regulatory T Cells.
Authors: Omar Duramad, Amy Laysang, Jun Li, Tuyen Trinh, Yasuyuki Ishii, Reiko Namikawa
Journal: Blood (2009)
Proposed primary endpoints for use in clinical trials that compare treatment options for bloodstream infection in adults: a consensus definition
Authors: P.N.A. Harris, J.F. McNamara, D.C. Lye, J.S. Davis, L. Bernard, A.C. Cheng, Y. Doi, V.G. Fowler, K.S. Kaye, L. Leibovici, J. Lipman, M.J. Llewelyn, S. Munoz-Price, M. Paul, A.Y. Peleg, J. Rodríguez-Baño, B.A. Rogers, H. Seifert, V. Thamlikitkul, G. Thwaites, S.Y.C. Tong, J. Turnidge, R. Utili, S.A.R. Webb, D.L. Paterson
Journal: Clinical Microbiology and Infection (2016)
Primer containing dimethylaminododecyl methacrylate kills bacteria impregnated in human dentin blocks
Authors: Chen Chen, Lei Cheng, Michael D Weir, Nancy J Lin, Sheng Lin-Gibson, Xue-Dong Zhou, Hockin HK Xu
Journal: International Journal of Oral Science (2016)

Antibacterial dimethylaminododecyl methacrylate (DMADDM) was recently synthesized. The objectives of this study were to: (1) investigate antibacterial activity of DMADDM-containing primer on Streptococcus mutans impregnated into dentin blocks for the first time, and (2) compare the antibacterial efficacy of DMADDM with a previous quaternary ammonium dimethacrylate (QADM). Scotchbond Multi-Purpose (SBMP) bonding agent was used. DMADDM and QADM were mixed into SBMP primer. Six primers were tested: SBMP control primer P, P+2.5% DMADDM, P+5% DMADDM, P+7.5% DMADDM, P+10% DMADDM, and P+10% QADM. S. mutans were impregnated into human dentin blocks, and each primer was applied to dentin to test its ability to kill bacteria in dentinal tubules. Bacteria in dentin were collected via a sonication method, and the colony-forming units (CFU) and inhibition zones were measured. The bacterial inhibition zone of P+10% DMADDM was 10 times that of control primer (P<0.05). CFU in dentin with P+10% DMADDM was reduced by three orders of magnitude, compared with control. DMADDM had a much stronger antibacterial effect than QADM, and antibacterial efficacy increased with increasing DMADDM concentration. Dentin shear bond strengths were similar among all groups (P>0.1). In conclusion, antibacterial DMADDM-containing primer was validated to kill bacteria inside dentin blocks, possessing a much stronger antibacterial potency than the previous QADM. DMADDM-containing bonding agent was effective in eradicating bacteria in dentin, and its efficacy was directly proportional to DMADDM mass fraction. Therefore, DMADDM may be promising for use in bonding agents as well as in other restorative and preventive materials to inhibit bacteria.
Standardized 4 Color Flow Cytometric Minimal Residual Disease Detection Failed To Overcome Regeneration Problems but Identifies Early Blast Clearence Predictive of Molecular Remission after Induction in Childhood B Lineage Leukemia.
Authors: Ester Mejstrikova, Eva Fronkova, Drago Batinic, Klara Dubravcic, Flora Kiss, Janos Kappelmayer, Drorit Luria, Alice Suk Hang Cheng, Batia Stark, Margaret Ng, Yonna Leung, Shai Izraeli, Martina Vaskova, Katerina Zdrahalova, Jan Trka, Jan Stary, Tomas Kalina, Ondrej Hrusak
Journal: Blood (2006)
Low‐level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment
Authors: Jung Hee Kim, Dong Hyun Sinn, Wonseok Kang, Geum‐Youn Gwak, Yong‐Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik
Journal: Hepatology (2016)

The long‐term clinical impact of low‐level viremia (LLV; &lt;2,000 IU/mL) is not well understood. As a result, it is unclear whether the development of LLV during entecavir monotherapy requires a change in therapy. A retrospective cohort of 875 treatment‐naive chronic hepatitis B virus (HBV) monoinfected patients (mean age 47.7 years, male = 564 [65.5%], cirrhosis = 443 [50.6%]) who received entecavir monotherapy were analyzed for the development of hepatocellular carcinoma (HCC). The HCC risk was compared between patients who maintained virological response (MVR), defined by persistently undetectable HBV DNA (&lt;12 IU/mL), and patients who experienced LLV, defined by either persistent or intermittent episodes of &lt;2,000 IU/mL detectable HBV DNA. During a median 4.5 years of follow‐up (range 1.0‐8.7 years), HCC was diagnosed in 85 patients (9.7%). HCC developed more frequently in patients who experienced LLV than MVR (14.3% versus 7.5% at 5 years, P = 0.015). The hazard ratio comparing those with LLV to MVR was 1.98 (95% confidence interval = 1.28‐3.06, P = 0.002, adjusted for age, sex, hepatitis B e antigen, baseline HBV DNA levels, and cirrhosis). Among patients with cirrhosis, those with LLV exhibited a significantly higher HCC risk than those with MVR (HCC incidence rate at 5 years 23.4% versus 10.3%, adjusted hazard ratio = 2.20, 95% confidence interval 1.34‐3.60; P = 0.002). However, for patients without cirrhosis, there was no significant difference in the HCC risk between LLV and MVR. Conclusion : LLV observed during entecavir monotherapy was associated with a higher risk of HCC, especially for those with cirrhosis, indicating that LLV during potent antiviral therapy is consequential. (H epatology 2017;66:335–343).
Acute Lung Inflammation in Sickle Mice Is Mediated by Increase of CXC Chemokines and Matrix Metalloproteinases
Authors: Carla Fernanda Franco-Penteado, Carolina Lanaro, Dulcinéia M Albuquerque, Ana Paula Gimenes, Luiz Augusto C Passos, Marcus A.F. Corat, Fernando F. Costa
Journal: Blood (2008)
Frequent Reduction or Absence of Detection of the JAK2-Mutated Clone in JAK2V617F-Positive Patients within the First Years of Hydroxyurea Therapy
Authors: François Girodon, C.éline Schaeffer, C.édric Cleyrat, Morgane Mounier, Ingrid Lafon, FréD.éric Dos Santos, Aurélie Duval, Marc Maynadie, Sylvie Hermouet
Journal: Blood (2008)
IDH1 Splicing Alterations in Patients with AML and Their Relationship to Blood 2HG Levels
Authors: Sophia Adamia, Patricia Toniolo, Amir T. Fathi, Ilene Galinsky, Suiyang Liu, Katharine Yen, Hyeryun Kim Kim, Dongwei Zhu, Straley Kim, Martha Wadleigh, David P. Steensma, Ibiayi Dagogo-Jack, Daniel J. DeAngelo, James D. Griffin, Richard M. Stone
Journal: Blood (2014)
O055 : Pushing the limits for tace: Selection for transarterial chemoembolisation treatment (state) score identifies HCC patients at BCLC stage C suitable for tace
Authors: F. Hucke, M. Pinter, I. Graziadei, S. Bota, W. Vogel, C.J. Millier, F. Wanek, M. Trauner, M. Peck-Radosavljevic, W. Sieghart
Journal: Journal of Hepatology (2015)
Personalized Treatment for a Patient With a<i>BRAF</i>V600E Mutation Using Dabrafenib and a Tumor Treatment Fields Device in a High-Grade Glioma Arising From Ganglioglioma
Authors: Silviya K. Meletath, Dean Pavlick, Tim Brennan, Roy Hamilton, Juliann Chmielecki, Julia A. Elvin, Norma Palma, Jeffrey S. Ross, Vincent A. Miller, Philip J. Stephens, George Snipes, Veena Rajaram, Siraj M. Ali, Isaac Melguizo-Gavilanes
Journal: Journal of the National Comprehensive Cancer Network (2016)

Background: Gangliogliomas are slow-growing, low-grade central nervous system tumors affecting children and young adults. However, some patients will experience tumor recurrence and/or malignant progression. This article reports on the clinical history, molecular findings, and treatment response in a patient with BRAF V600–mutated high-grade glioma arising from ganglioglioma. Methods: Hematoxylin-eosin staining and comprehensive genomic profiling via Foundation One were performed on the tumor sample from a male patient undergoing treatment at the Department of Neuro-Oncology at Baylor University Medical Center. Results: The patient was eligible for participation in a clinical trial (ClinicalTrials.gov identifier: NCT00916409) of a tumor treatment fields (TTFields) device, NovoTTF-100A, with concurrent radiation and chemotherapy (CCRT). His disease relapsed 4 months after completion of his CCRT, with MRI showing areas of enhancement. Temozolomide was discontinued and he was offered dabrafenib, an oral selective inhibitor of BRAF V600E, with continued use of NovoTTF. At the time of this report, after 2 years of treatment with dabrafenib and TTFields, the patient shows a durable complete response in all areas with no active lesions or new areas of enhancement. Conclusions: This report suggests that TTFields delivered in combination with targeted therapy dabrafenib yielded a remarkable clinical and radiologic response in this recurrent high-grade glioma. Targeted therapy matched to genomic alterations combined with TTFields treatment could provide clinical benefit and should be prospectively explored in the near future.
Simultaneous Targeting of Lyn and Bcr-Abl Kinases by NS-187 Cures Mice Bearing Imatinib-Resistant Leukemic Cells.
Authors: Haruna Naito, Shinya Kimura, Yohei Nakaya, Haruna Naruoka, Tatsushi Wakayama, Sachie Kimura, Shinsaku Ito, Eishi Ashihara, Taira Maekawa, Kazuko Hirabayashi
Journal: Blood (2005)
A Novel Technique For Digital Analysis Enables Cell-Type Specific Quantification In Pulmonary Vascular Immunofluorescence
Authors: Q. A. J. Hagdorn, L. M. Jorna, D. E. Van der Feen, J. R. Moonen, R. M. F. Berger, B. Bartelds
Journal: American Journal of Respiratory and Critical Care Medicine (2015)
Prognostic Value of the Rate of BCR-ABL Decline for Patients with Chronic Myelogenous Leukemia in Chronic Phase on Tyrosine Kinase Inhibitors Treatment
Authors: Vasily Shuvaev, Mikhail Fominykh, Martynkevich Irina, Grigory Tsaur, Natalya Bederak, Ekaterina Chelysheva, Oleg Shukhov, Alla Abdulkadyrova, Vera Udaleva, Regina Golovchenko, Irina Zotova, Adhamjon Abdullaev, Dzhariyat Shikhbabaeva, Lyubov Polushkina, Ekaterina Petrova, Lyudmila Martynenko, Elizaveta Kleina, Natalya Cybakova, Marina Ivanova, Anna G. Turkina, Kudrat Abdulkadyrov
Journal: Blood (2014)
Multiple Myeloma-Derived Bone-Marrow Mesenchymal Stem Cells: Microrna-, Gene Expression-Profiling and Functional Characterization
Authors: Michaela R Reagan, Aldo M Roccaro, AbdelKareem Azab, Yong Zhang, Grace B O'Callaghan, Patricia Maiso, Salomon Manier, David L. Kaplan, Irene M. Ghobrial
Journal: Blood (2012)
Case 29-1974
Authors: Richard C. Cabot, Robert E. Scully, Betty U. McNeely, Robert P. McCombs, James J. Galdabini
Journal: New England Journal of Medicine (1974)

Presentation of CaseA 55-year-old woman was admitted to the hospital because of hemoptysis.She was well until two months previously, when there was the onset of symptoms of a respiratory-tract infection, characterized by a nonproductive cough, low-grade fever, chilliness and arthralgia. Ampicillin and tetracycline were given, without benefit. The cough and episodic chilliness persisted, and she experienced aches in the joints and muscles. One week before admission anorexia and nausea developed. Five days before entry the temperature rose to 38.8°C, and she coughed up small blood clots. She was taken to another hospital, where an x-ray film of the . . .
Reduction in the Incidence and Severity of Graft Versus Host Disease in HLA-Matched and Haploidentical Bone Marrow Transplantation Using Posttrasplant Cyclophosphamide. Experience of Two Latino-American Institutions
Authors: Roberto Ovilla, Uendy Perez-Lozano, Dannia Calles-Payan, Lucia A Reynolds-Ocampo, Gabriela Ruiz-Reyes, Carolina Balderas-Delgado, Alvaro Cabrera Garcia
Journal: Blood (2014)
Unusual Presentations of Lymphoma
Authors: Parthas Narasimhan, Ibrahim F. Hitti, Parul Gheewala, Usha Pulakhandam, Barry Kanzer
Journal: Journal of Clinical Oncology (2002)

Article Tools DIAGNOSIS IN ONCOLOGY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2002.20.7.1946 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 11919257 Unusual Presentations of Lymphoma Case 3. Splenic Hematoma Associated With Non-Hodgkin's Lymphoma Parthas NarasimhanxParthas NarasimhanSearch for articles by this author , Ibrahim F. HittixIbrahim F. HittiSearch for articles by this author , Parul GheewalaxParul GheewalaSearch for articles by this author , Usha PulakhandamxUsha PulakhandamSearch for articles by this author , Barry KanzerxBarry KanzerSearch for articles by this author Show More North Shore University Hospital at Forest Hills, Forest Hills, NY https://doi.org/10.1200/JCO.2002.20.7.1946 First Page Full Text PDF Figures and Tables © 2002 by American Society of Clinical Oncology
MUSCLE INJURIES OF THE DOMINANT OR NON-DOMINANT LEG IN MALE FOOTBALL PLAYERS AT ELITE LEVEL
Authors: K Svensson, M Eckerman, M Alricsson, T Magounakis, S Werner
Journal: British Journal of Sports Medicine (2016)

Football is one of the most popular sports worldwide. Unfortunately, football players are highly exposed to injuries and muscle injuries are the most common ones. The aim was to study possible differences of muscle injuries regarding type, localization and the extent of injury between the dominant and non-dominant leg in elite male football players. Another aim was to study the injury incidence of muscle injuries of the lower extremity during match and training. Data were consecutively collected between 2007 and 2013 in a prospective cohort study based on fifty-four football players from one team of the Swedish first league. The injury incidence was calculated for both match and training and injuries to the hip adductors, quadriceps, hamstrings and triceps surae were diagnosed and evaluated with ultrasonography and their length, depth and width were measured to determine the extent of structural muscle injuries. Fifty-four players suffered totally 105 of the studied muscle injuries. Out of these 105 injuries the dominant leg was affected in 53% (n=56) of the cases. A greater extent of the injury was found in the dominant leg when compared to the non-dominant leg with regards to structural injuries of the hamstrings. No other significant differences were found. Structural hamstring muscle injuries were found to be of greater extent in the dominant leg when compared to the non-dominant leg. This new finding should be taken into consideration when allowing the football player to return to play after leg muscle injuries.
Legally aided medical negligence cases fall sharply
Authors: Roger Dobson
Journal: BMJ (2001)

The number of legally aided cases alleging medical negligence has more than halved in the past year.

New figures for England and Wales from the Legal Services Commission will show that over the past 12 months, only 6197 cases were given the go ahead compared with a peak of 13 366 in 1995-6. The big drop is being put down to the use of specialist law firms, which are better able to filter out cases unlikely to succeed; tighter controls on the use of legal aid; and the diversion of some cases to the NHS complaints procedure.

“These figures are very much against a public …
GDP (Gemcitabine, Dexamethasone, Cisplatin) Salvage Therapy Results in Superior Progression Free Survival Compared to Mini-Beam Prior to Autologous Stem Cell Transplantation for Relapsed or Refractory Hodgkin’s Lymphoma.
Authors: John Kuruvilla, Tracy Nagy, Melania Pintilie, Armand Keating, Michael Crump
Journal: Blood (2004)
Prognostic Impact of Monosomy 7 as a Single Anomaly In Primary MDS – Reclassification From Poor to Intermediate Prognosis
Authors: Julie Schanz, Heinz Tüchler, Francesc Sole, Mar Mallo, Barbara Hildebrandt, Christian Steidl, Christa Fonatsch, Michael Pfeilstöcker, Thomas Nösslinger, Peter Valent, Aristoteles Giagounidis, Michael Lübbert, Reinhard Stauder, Otto Krieger, Michelle M. Le Beau, John M. Bennett, Peter L. Greenberg, Ulrich Germing, Detlef Haase
Journal: Blood (2010)
STAAR: a randomised controlled trial of electronic adherence monitoring with reminder alarms and feedback to improve clinical outcomes for children with asthma
Authors: Robert W Morton, Heather E Elphick, Alan S Rigby, William J Daw, David A King, Laurie J Smith, Mark L Everard
Journal: Thorax (2016)

Suboptimal adherence to inhaled steroids is common in children with asthma and is associated with poor disease control, reduced quality of life and even death. Previous studies using feedback of electronically monitored adherence data have demonstrated improved adherence, but have not demonstrated a significant impact on clinical outcomes. The aim of this study was to determine whether introduction of this approach into routine practice would result in improved clinical outcomes.Children with asthma aged 6-16 years were randomised to the active intervention consisting of electronic adherence monitoring with daily reminder alarms together with feedback in the clinic regarding their inhaled corticosteroid (ICS) use or to the usual care arm with adherence monitoring alone. All children had poorly controlled asthma at baseline, taking ICS and long-acting β-agonists. Subjects were seen in routine clinics every 3 months for 1 year. The primary outcome was the Asthma Control Questionnaire (ACQ) score. Secondary outcomes included adherence and markers of asthma morbidity.77 of 90 children completed the study (39 interventions, 38 controls). Adherence in the intervention group was 70% vs 49% in the control group (p≤0.001). There was no significant difference in the change in ACQ, but children in the intervention group required significantly fewer courses of oral steroids (p=0.008) and fewer hospital admissions (p≤0.001).The results indicate that electronic adherence monitoring with feedback is likely to be of significant benefit in the routine management of poorly controlled asthmatic subjects.NCT02451709; pre-result.